Two-Year Outcomes of Anticoagulation for Acute Ischemic Stroke With Nonvalvular Atrial Fibrillation ― SAMURAI-NVAF Study
Background:We determined the 2-year long-term risk-benefit profile in patients with stroke or transient ischemic attack (TIA) receiving warfarin or direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (NVAF) using a prospective, multicenter, observational registry in Japan.Methods ...
Gespeichert in:
| Veröffentlicht in: | Circulation Journal 2018/06/25, Vol.82(7), pp.1935-1942 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1942 |
|---|---|
| container_issue | 7 |
| container_start_page | 1935 |
| container_title | Circulation Journal |
| container_volume | 82 |
| creator | Yoshimura, Sohei Koga, Masatoshi Sato, Shoichiro Todo, Kenichi Yamagami, Hiroshi Kumamoto, Masaya Itabashi, Ryo Terasaki, Tadashi Kimura, Kazumi Yagita, Yoshiki Shiokawa, Yoshiaki Kamiyama, Kenji Okuda, Satoshi Okada, Yasushi Takizawa, Shunya Hasegawa, Yasuhiro Kameda, Tomoaki Shibuya, Satoshi Nagakane, Yoshinari Ito, Yasuhiro Matsuoka, Hideki Takamatsu, Kazuhiro Nishiyama, Kazutoshi Fujita, Kyohei Kamimura, Teppei Ando, Daisuke Ide, Toshihiro Yoshimoto, Takeshi Shiozawa, Masayuki Matsubara, Soichiro Yamaguchi, Yoshitaka Kinoshita, Naoto Matsuki, Takayuki Takasugi, Junji Tokunaga, Keisuke Higashida, Kyoko Homma, Kazunari Kario, Kazuomi Arihiro, Shoji Toyoda, Kazunori for the SAMURAI Study Investigators |
| description | Background:We determined the 2-year long-term risk-benefit profile in patients with stroke or transient ischemic attack (TIA) receiving warfarin or direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (NVAF) using a prospective, multicenter, observational registry in Japan.Methods and Results:NVAF patients within 7 days after onset of ischemic stroke/TIA were enrolled in 18 stroke centers. Outcome measures included ischemic and bleeding events and death in the 2-year follow-up period. We enrolled 1,116 patients taking either warfarin (650 patients) or DOACs (466 patients) at acute hospital discharge. DOAC users were younger and had lower National Institutes of Health Stroke Scale, CHADS2and discharge modified Rankin Scale scores than warfarin users (P |
| doi_str_mv | 10.1253/circj.CJ-18-0067 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2049932268</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2049932268</sourcerecordid><originalsourceid>FETCH-LOGICAL-c494t-4aacc71081cc9f187856cbf5c762c7d5192643884b8e16d2afbdc7bb2511b4b33</originalsourceid><addsrcrecordid>eNpFkMtu1DAUhi1ERUthzwp5ycbFtyT2MhoxdKrSSr2AWFm243Q8JHGxnVaVWMxL8ILwImQ6Q7s55yy-_9fRB8A7go8ILdhH66NdHc1OEBEI47J6AQ4I4xXiguKXj3eJpOBsH7xOaYUxlbiQr8A-laJkWBYH4NfVfUDfnY7wfMw29C7B0MJ6yN4GfTN2OvswwDZEWNsxO7hIdul6b-FljuGHg998XsKzMNzp7m6iJyxHrzs49yb6bhv_u17_Wf-Gl_WX64t6gc6-1vMpPjYPb8Beq7vk3u72Ibief7qaHaPT88-LWX2KLJc8I661tRXBglgrWyIqUZTWtIWtSmqrpiCSlpwJwY1wpGyobk1jK2NoQYjhhrFD8GHbexvDz9GlrHqfrJveG1wYk6KYS8koLcWE4i1qY0gpulbdRt_r-KAIVhvn6tG5mp0oItTG-RR5v2sfTe-ap8B_yRMw3wKrlPWNewJ0nCx3btcoqKo247n5GVjqqNzA_gG_0pna</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2049932268</pqid></control><display><type>article</type><title>Two-Year Outcomes of Anticoagulation for Acute Ischemic Stroke With Nonvalvular Atrial Fibrillation ― SAMURAI-NVAF Study</title><source>MEDLINE</source><source>EZB Electronic Journals Library</source><source>J-STAGE</source><creator>Yoshimura, Sohei ; Koga, Masatoshi ; Sato, Shoichiro ; Todo, Kenichi ; Yamagami, Hiroshi ; Kumamoto, Masaya ; Itabashi, Ryo ; Terasaki, Tadashi ; Kimura, Kazumi ; Yagita, Yoshiki ; Shiokawa, Yoshiaki ; Kamiyama, Kenji ; Okuda, Satoshi ; Okada, Yasushi ; Takizawa, Shunya ; Hasegawa, Yasuhiro ; Kameda, Tomoaki ; Shibuya, Satoshi ; Nagakane, Yoshinari ; Ito, Yasuhiro ; Matsuoka, Hideki ; Takamatsu, Kazuhiro ; Nishiyama, Kazutoshi ; Fujita, Kyohei ; Kamimura, Teppei ; Ando, Daisuke ; Ide, Toshihiro ; Yoshimoto, Takeshi ; Shiozawa, Masayuki ; Matsubara, Soichiro ; Yamaguchi, Yoshitaka ; Kinoshita, Naoto ; Matsuki, Takayuki ; Takasugi, Junji ; Tokunaga, Keisuke ; Higashida, Kyoko ; Homma, Kazunari ; Kario, Kazuomi ; Arihiro, Shoji ; Toyoda, Kazunori ; for the SAMURAI Study Investigators</creator><creatorcontrib>Yoshimura, Sohei ; Koga, Masatoshi ; Sato, Shoichiro ; Todo, Kenichi ; Yamagami, Hiroshi ; Kumamoto, Masaya ; Itabashi, Ryo ; Terasaki, Tadashi ; Kimura, Kazumi ; Yagita, Yoshiki ; Shiokawa, Yoshiaki ; Kamiyama, Kenji ; Okuda, Satoshi ; Okada, Yasushi ; Takizawa, Shunya ; Hasegawa, Yasuhiro ; Kameda, Tomoaki ; Shibuya, Satoshi ; Nagakane, Yoshinari ; Ito, Yasuhiro ; Matsuoka, Hideki ; Takamatsu, Kazuhiro ; Nishiyama, Kazutoshi ; Fujita, Kyohei ; Kamimura, Teppei ; Ando, Daisuke ; Ide, Toshihiro ; Yoshimoto, Takeshi ; Shiozawa, Masayuki ; Matsubara, Soichiro ; Yamaguchi, Yoshitaka ; Kinoshita, Naoto ; Matsuki, Takayuki ; Takasugi, Junji ; Tokunaga, Keisuke ; Higashida, Kyoko ; Homma, Kazunari ; Kario, Kazuomi ; Arihiro, Shoji ; Toyoda, Kazunori ; for the SAMURAI Study Investigators ; SAMURAI Study Investigators ; for the SAMURAI Study Investigators</creatorcontrib><description>Background:We determined the 2-year long-term risk-benefit profile in patients with stroke or transient ischemic attack (TIA) receiving warfarin or direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (NVAF) using a prospective, multicenter, observational registry in Japan.Methods and Results:NVAF patients within 7 days after onset of ischemic stroke/TIA were enrolled in 18 stroke centers. Outcome measures included ischemic and bleeding events and death in the 2-year follow-up period. We enrolled 1,116 patients taking either warfarin (650 patients) or DOACs (466 patients) at acute hospital discharge. DOAC users were younger and had lower National Institutes of Health Stroke Scale, CHADS2and discharge modified Rankin Scale scores than warfarin users (P<0.0001 each). Incidences of stroke/systemic embolism (adjusted hazard ratio, 1.07; 95% CI, 0.66–1.72), all ischemic events (1.13; 0.72–1.75), and ischemic stroke/TIA (1.58; 0.95–2.62) were similar between groups. Risks of intracranial hemorrhage (0.32; 0.09–0.97) and death (0.41; 0.26–0.63) were significantly lower for DOAC users. Infection was the leading cause of death, accounting for 40% of deaths among warfarin users.Conclusions:Stroke/TIA patients receiving DOACs for secondary prevention were younger and had lower stroke severity and risk indices than those receiving warfarin. Estimated cumulative incidences of stroke and systemic embolism within 2 years were similar between warfarin and DOACs users, but those of death and intracranial hemorrhage were significantly lower among DOAC users.</description><identifier>ISSN: 1346-9843</identifier><identifier>ISSN: 1347-4820</identifier><identifier>EISSN: 1347-4820</identifier><identifier>DOI: 10.1253/circj.CJ-18-0067</identifier><identifier>PMID: 29863095</identifier><language>eng</language><publisher>Japan: The Japanese Circulation Society</publisher><subject>Acute stroke ; Administration, Oral ; Aged ; Aged, 80 and over ; Anticoagulants - administration & dosage ; Anticoagulants - adverse effects ; Anticoagulants - therapeutic use ; Atrial fibrillation ; Atrial Fibrillation - drug therapy ; Brain Ischemia - chemically induced ; Direct oral anticoagulants ; Female ; Follow-Up Studies ; Humans ; Infections - chemically induced ; Intracranial hemorrhage ; Ischemic Attack, Transient - drug therapy ; Japan ; Male ; Middle Aged ; Prospective Studies ; Registries ; Stroke - drug therapy ; Survival Analysis ; Treatment Outcome ; Warfarin ; Warfarin - adverse effects ; Warfarin - therapeutic use</subject><ispartof>Circulation Journal, 2018/06/25, Vol.82(7), pp.1935-1942</ispartof><rights>2018 THE JAPANESE CIRCULATION SOCIETY</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c494t-4aacc71081cc9f187856cbf5c762c7d5192643884b8e16d2afbdc7bb2511b4b33</citedby><cites>FETCH-LOGICAL-c494t-4aacc71081cc9f187856cbf5c762c7d5192643884b8e16d2afbdc7bb2511b4b33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29863095$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yoshimura, Sohei</creatorcontrib><creatorcontrib>Koga, Masatoshi</creatorcontrib><creatorcontrib>Sato, Shoichiro</creatorcontrib><creatorcontrib>Todo, Kenichi</creatorcontrib><creatorcontrib>Yamagami, Hiroshi</creatorcontrib><creatorcontrib>Kumamoto, Masaya</creatorcontrib><creatorcontrib>Itabashi, Ryo</creatorcontrib><creatorcontrib>Terasaki, Tadashi</creatorcontrib><creatorcontrib>Kimura, Kazumi</creatorcontrib><creatorcontrib>Yagita, Yoshiki</creatorcontrib><creatorcontrib>Shiokawa, Yoshiaki</creatorcontrib><creatorcontrib>Kamiyama, Kenji</creatorcontrib><creatorcontrib>Okuda, Satoshi</creatorcontrib><creatorcontrib>Okada, Yasushi</creatorcontrib><creatorcontrib>Takizawa, Shunya</creatorcontrib><creatorcontrib>Hasegawa, Yasuhiro</creatorcontrib><creatorcontrib>Kameda, Tomoaki</creatorcontrib><creatorcontrib>Shibuya, Satoshi</creatorcontrib><creatorcontrib>Nagakane, Yoshinari</creatorcontrib><creatorcontrib>Ito, Yasuhiro</creatorcontrib><creatorcontrib>Matsuoka, Hideki</creatorcontrib><creatorcontrib>Takamatsu, Kazuhiro</creatorcontrib><creatorcontrib>Nishiyama, Kazutoshi</creatorcontrib><creatorcontrib>Fujita, Kyohei</creatorcontrib><creatorcontrib>Kamimura, Teppei</creatorcontrib><creatorcontrib>Ando, Daisuke</creatorcontrib><creatorcontrib>Ide, Toshihiro</creatorcontrib><creatorcontrib>Yoshimoto, Takeshi</creatorcontrib><creatorcontrib>Shiozawa, Masayuki</creatorcontrib><creatorcontrib>Matsubara, Soichiro</creatorcontrib><creatorcontrib>Yamaguchi, Yoshitaka</creatorcontrib><creatorcontrib>Kinoshita, Naoto</creatorcontrib><creatorcontrib>Matsuki, Takayuki</creatorcontrib><creatorcontrib>Takasugi, Junji</creatorcontrib><creatorcontrib>Tokunaga, Keisuke</creatorcontrib><creatorcontrib>Higashida, Kyoko</creatorcontrib><creatorcontrib>Homma, Kazunari</creatorcontrib><creatorcontrib>Kario, Kazuomi</creatorcontrib><creatorcontrib>Arihiro, Shoji</creatorcontrib><creatorcontrib>Toyoda, Kazunori</creatorcontrib><creatorcontrib>for the SAMURAI Study Investigators</creatorcontrib><creatorcontrib>SAMURAI Study Investigators</creatorcontrib><creatorcontrib>for the SAMURAI Study Investigators</creatorcontrib><title>Two-Year Outcomes of Anticoagulation for Acute Ischemic Stroke With Nonvalvular Atrial Fibrillation ― SAMURAI-NVAF Study</title><title>Circulation Journal</title><addtitle>Circ J</addtitle><description>Background:We determined the 2-year long-term risk-benefit profile in patients with stroke or transient ischemic attack (TIA) receiving warfarin or direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (NVAF) using a prospective, multicenter, observational registry in Japan.Methods and Results:NVAF patients within 7 days after onset of ischemic stroke/TIA were enrolled in 18 stroke centers. Outcome measures included ischemic and bleeding events and death in the 2-year follow-up period. We enrolled 1,116 patients taking either warfarin (650 patients) or DOACs (466 patients) at acute hospital discharge. DOAC users were younger and had lower National Institutes of Health Stroke Scale, CHADS2and discharge modified Rankin Scale scores than warfarin users (P<0.0001 each). Incidences of stroke/systemic embolism (adjusted hazard ratio, 1.07; 95% CI, 0.66–1.72), all ischemic events (1.13; 0.72–1.75), and ischemic stroke/TIA (1.58; 0.95–2.62) were similar between groups. Risks of intracranial hemorrhage (0.32; 0.09–0.97) and death (0.41; 0.26–0.63) were significantly lower for DOAC users. Infection was the leading cause of death, accounting for 40% of deaths among warfarin users.Conclusions:Stroke/TIA patients receiving DOACs for secondary prevention were younger and had lower stroke severity and risk indices than those receiving warfarin. Estimated cumulative incidences of stroke and systemic embolism within 2 years were similar between warfarin and DOACs users, but those of death and intracranial hemorrhage were significantly lower among DOAC users.</description><subject>Acute stroke</subject><subject>Administration, Oral</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anticoagulants - administration & dosage</subject><subject>Anticoagulants - adverse effects</subject><subject>Anticoagulants - therapeutic use</subject><subject>Atrial fibrillation</subject><subject>Atrial Fibrillation - drug therapy</subject><subject>Brain Ischemia - chemically induced</subject><subject>Direct oral anticoagulants</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Infections - chemically induced</subject><subject>Intracranial hemorrhage</subject><subject>Ischemic Attack, Transient - drug therapy</subject><subject>Japan</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prospective Studies</subject><subject>Registries</subject><subject>Stroke - drug therapy</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>Warfarin</subject><subject>Warfarin - adverse effects</subject><subject>Warfarin - therapeutic use</subject><issn>1346-9843</issn><issn>1347-4820</issn><issn>1347-4820</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMtu1DAUhi1ERUthzwp5ycbFtyT2MhoxdKrSSr2AWFm243Q8JHGxnVaVWMxL8ILwImQ6Q7s55yy-_9fRB8A7go8ILdhH66NdHc1OEBEI47J6AQ4I4xXiguKXj3eJpOBsH7xOaYUxlbiQr8A-laJkWBYH4NfVfUDfnY7wfMw29C7B0MJ6yN4GfTN2OvswwDZEWNsxO7hIdul6b-FljuGHg998XsKzMNzp7m6iJyxHrzs49yb6bhv_u17_Wf-Gl_WX64t6gc6-1vMpPjYPb8Beq7vk3u72Ibief7qaHaPT88-LWX2KLJc8I661tRXBglgrWyIqUZTWtIWtSmqrpiCSlpwJwY1wpGyobk1jK2NoQYjhhrFD8GHbexvDz9GlrHqfrJveG1wYk6KYS8koLcWE4i1qY0gpulbdRt_r-KAIVhvn6tG5mp0oItTG-RR5v2sfTe-ap8B_yRMw3wKrlPWNewJ0nCx3btcoqKo247n5GVjqqNzA_gG_0pna</recordid><startdate>20180625</startdate><enddate>20180625</enddate><creator>Yoshimura, Sohei</creator><creator>Koga, Masatoshi</creator><creator>Sato, Shoichiro</creator><creator>Todo, Kenichi</creator><creator>Yamagami, Hiroshi</creator><creator>Kumamoto, Masaya</creator><creator>Itabashi, Ryo</creator><creator>Terasaki, Tadashi</creator><creator>Kimura, Kazumi</creator><creator>Yagita, Yoshiki</creator><creator>Shiokawa, Yoshiaki</creator><creator>Kamiyama, Kenji</creator><creator>Okuda, Satoshi</creator><creator>Okada, Yasushi</creator><creator>Takizawa, Shunya</creator><creator>Hasegawa, Yasuhiro</creator><creator>Kameda, Tomoaki</creator><creator>Shibuya, Satoshi</creator><creator>Nagakane, Yoshinari</creator><creator>Ito, Yasuhiro</creator><creator>Matsuoka, Hideki</creator><creator>Takamatsu, Kazuhiro</creator><creator>Nishiyama, Kazutoshi</creator><creator>Fujita, Kyohei</creator><creator>Kamimura, Teppei</creator><creator>Ando, Daisuke</creator><creator>Ide, Toshihiro</creator><creator>Yoshimoto, Takeshi</creator><creator>Shiozawa, Masayuki</creator><creator>Matsubara, Soichiro</creator><creator>Yamaguchi, Yoshitaka</creator><creator>Kinoshita, Naoto</creator><creator>Matsuki, Takayuki</creator><creator>Takasugi, Junji</creator><creator>Tokunaga, Keisuke</creator><creator>Higashida, Kyoko</creator><creator>Homma, Kazunari</creator><creator>Kario, Kazuomi</creator><creator>Arihiro, Shoji</creator><creator>Toyoda, Kazunori</creator><creator>for the SAMURAI Study Investigators</creator><general>The Japanese Circulation Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20180625</creationdate><title>Two-Year Outcomes of Anticoagulation for Acute Ischemic Stroke With Nonvalvular Atrial Fibrillation ― SAMURAI-NVAF Study</title><author>Yoshimura, Sohei ; Koga, Masatoshi ; Sato, Shoichiro ; Todo, Kenichi ; Yamagami, Hiroshi ; Kumamoto, Masaya ; Itabashi, Ryo ; Terasaki, Tadashi ; Kimura, Kazumi ; Yagita, Yoshiki ; Shiokawa, Yoshiaki ; Kamiyama, Kenji ; Okuda, Satoshi ; Okada, Yasushi ; Takizawa, Shunya ; Hasegawa, Yasuhiro ; Kameda, Tomoaki ; Shibuya, Satoshi ; Nagakane, Yoshinari ; Ito, Yasuhiro ; Matsuoka, Hideki ; Takamatsu, Kazuhiro ; Nishiyama, Kazutoshi ; Fujita, Kyohei ; Kamimura, Teppei ; Ando, Daisuke ; Ide, Toshihiro ; Yoshimoto, Takeshi ; Shiozawa, Masayuki ; Matsubara, Soichiro ; Yamaguchi, Yoshitaka ; Kinoshita, Naoto ; Matsuki, Takayuki ; Takasugi, Junji ; Tokunaga, Keisuke ; Higashida, Kyoko ; Homma, Kazunari ; Kario, Kazuomi ; Arihiro, Shoji ; Toyoda, Kazunori ; for the SAMURAI Study Investigators</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c494t-4aacc71081cc9f187856cbf5c762c7d5192643884b8e16d2afbdc7bb2511b4b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Acute stroke</topic><topic>Administration, Oral</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anticoagulants - administration & dosage</topic><topic>Anticoagulants - adverse effects</topic><topic>Anticoagulants - therapeutic use</topic><topic>Atrial fibrillation</topic><topic>Atrial Fibrillation - drug therapy</topic><topic>Brain Ischemia - chemically induced</topic><topic>Direct oral anticoagulants</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Infections - chemically induced</topic><topic>Intracranial hemorrhage</topic><topic>Ischemic Attack, Transient - drug therapy</topic><topic>Japan</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prospective Studies</topic><topic>Registries</topic><topic>Stroke - drug therapy</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>Warfarin</topic><topic>Warfarin - adverse effects</topic><topic>Warfarin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoshimura, Sohei</creatorcontrib><creatorcontrib>Koga, Masatoshi</creatorcontrib><creatorcontrib>Sato, Shoichiro</creatorcontrib><creatorcontrib>Todo, Kenichi</creatorcontrib><creatorcontrib>Yamagami, Hiroshi</creatorcontrib><creatorcontrib>Kumamoto, Masaya</creatorcontrib><creatorcontrib>Itabashi, Ryo</creatorcontrib><creatorcontrib>Terasaki, Tadashi</creatorcontrib><creatorcontrib>Kimura, Kazumi</creatorcontrib><creatorcontrib>Yagita, Yoshiki</creatorcontrib><creatorcontrib>Shiokawa, Yoshiaki</creatorcontrib><creatorcontrib>Kamiyama, Kenji</creatorcontrib><creatorcontrib>Okuda, Satoshi</creatorcontrib><creatorcontrib>Okada, Yasushi</creatorcontrib><creatorcontrib>Takizawa, Shunya</creatorcontrib><creatorcontrib>Hasegawa, Yasuhiro</creatorcontrib><creatorcontrib>Kameda, Tomoaki</creatorcontrib><creatorcontrib>Shibuya, Satoshi</creatorcontrib><creatorcontrib>Nagakane, Yoshinari</creatorcontrib><creatorcontrib>Ito, Yasuhiro</creatorcontrib><creatorcontrib>Matsuoka, Hideki</creatorcontrib><creatorcontrib>Takamatsu, Kazuhiro</creatorcontrib><creatorcontrib>Nishiyama, Kazutoshi</creatorcontrib><creatorcontrib>Fujita, Kyohei</creatorcontrib><creatorcontrib>Kamimura, Teppei</creatorcontrib><creatorcontrib>Ando, Daisuke</creatorcontrib><creatorcontrib>Ide, Toshihiro</creatorcontrib><creatorcontrib>Yoshimoto, Takeshi</creatorcontrib><creatorcontrib>Shiozawa, Masayuki</creatorcontrib><creatorcontrib>Matsubara, Soichiro</creatorcontrib><creatorcontrib>Yamaguchi, Yoshitaka</creatorcontrib><creatorcontrib>Kinoshita, Naoto</creatorcontrib><creatorcontrib>Matsuki, Takayuki</creatorcontrib><creatorcontrib>Takasugi, Junji</creatorcontrib><creatorcontrib>Tokunaga, Keisuke</creatorcontrib><creatorcontrib>Higashida, Kyoko</creatorcontrib><creatorcontrib>Homma, Kazunari</creatorcontrib><creatorcontrib>Kario, Kazuomi</creatorcontrib><creatorcontrib>Arihiro, Shoji</creatorcontrib><creatorcontrib>Toyoda, Kazunori</creatorcontrib><creatorcontrib>for the SAMURAI Study Investigators</creatorcontrib><creatorcontrib>SAMURAI Study Investigators</creatorcontrib><creatorcontrib>for the SAMURAI Study Investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoshimura, Sohei</au><au>Koga, Masatoshi</au><au>Sato, Shoichiro</au><au>Todo, Kenichi</au><au>Yamagami, Hiroshi</au><au>Kumamoto, Masaya</au><au>Itabashi, Ryo</au><au>Terasaki, Tadashi</au><au>Kimura, Kazumi</au><au>Yagita, Yoshiki</au><au>Shiokawa, Yoshiaki</au><au>Kamiyama, Kenji</au><au>Okuda, Satoshi</au><au>Okada, Yasushi</au><au>Takizawa, Shunya</au><au>Hasegawa, Yasuhiro</au><au>Kameda, Tomoaki</au><au>Shibuya, Satoshi</au><au>Nagakane, Yoshinari</au><au>Ito, Yasuhiro</au><au>Matsuoka, Hideki</au><au>Takamatsu, Kazuhiro</au><au>Nishiyama, Kazutoshi</au><au>Fujita, Kyohei</au><au>Kamimura, Teppei</au><au>Ando, Daisuke</au><au>Ide, Toshihiro</au><au>Yoshimoto, Takeshi</au><au>Shiozawa, Masayuki</au><au>Matsubara, Soichiro</au><au>Yamaguchi, Yoshitaka</au><au>Kinoshita, Naoto</au><au>Matsuki, Takayuki</au><au>Takasugi, Junji</au><au>Tokunaga, Keisuke</au><au>Higashida, Kyoko</au><au>Homma, Kazunari</au><au>Kario, Kazuomi</au><au>Arihiro, Shoji</au><au>Toyoda, Kazunori</au><au>for the SAMURAI Study Investigators</au><aucorp>SAMURAI Study Investigators</aucorp><aucorp>for the SAMURAI Study Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Two-Year Outcomes of Anticoagulation for Acute Ischemic Stroke With Nonvalvular Atrial Fibrillation ― SAMURAI-NVAF Study</atitle><jtitle>Circulation Journal</jtitle><addtitle>Circ J</addtitle><date>2018-06-25</date><risdate>2018</risdate><volume>82</volume><issue>7</issue><spage>1935</spage><epage>1942</epage><pages>1935-1942</pages><issn>1346-9843</issn><issn>1347-4820</issn><eissn>1347-4820</eissn><abstract>Background:We determined the 2-year long-term risk-benefit profile in patients with stroke or transient ischemic attack (TIA) receiving warfarin or direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (NVAF) using a prospective, multicenter, observational registry in Japan.Methods and Results:NVAF patients within 7 days after onset of ischemic stroke/TIA were enrolled in 18 stroke centers. Outcome measures included ischemic and bleeding events and death in the 2-year follow-up period. We enrolled 1,116 patients taking either warfarin (650 patients) or DOACs (466 patients) at acute hospital discharge. DOAC users were younger and had lower National Institutes of Health Stroke Scale, CHADS2and discharge modified Rankin Scale scores than warfarin users (P<0.0001 each). Incidences of stroke/systemic embolism (adjusted hazard ratio, 1.07; 95% CI, 0.66–1.72), all ischemic events (1.13; 0.72–1.75), and ischemic stroke/TIA (1.58; 0.95–2.62) were similar between groups. Risks of intracranial hemorrhage (0.32; 0.09–0.97) and death (0.41; 0.26–0.63) were significantly lower for DOAC users. Infection was the leading cause of death, accounting for 40% of deaths among warfarin users.Conclusions:Stroke/TIA patients receiving DOACs for secondary prevention were younger and had lower stroke severity and risk indices than those receiving warfarin. Estimated cumulative incidences of stroke and systemic embolism within 2 years were similar between warfarin and DOACs users, but those of death and intracranial hemorrhage were significantly lower among DOAC users.</abstract><cop>Japan</cop><pub>The Japanese Circulation Society</pub><pmid>29863095</pmid><doi>10.1253/circj.CJ-18-0067</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1346-9843 |
| ispartof | Circulation Journal, 2018/06/25, Vol.82(7), pp.1935-1942 |
| issn | 1346-9843 1347-4820 1347-4820 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2049932268 |
| source | MEDLINE; EZB Electronic Journals Library; J-STAGE |
| subjects | Acute stroke Administration, Oral Aged Aged, 80 and over Anticoagulants - administration & dosage Anticoagulants - adverse effects Anticoagulants - therapeutic use Atrial fibrillation Atrial Fibrillation - drug therapy Brain Ischemia - chemically induced Direct oral anticoagulants Female Follow-Up Studies Humans Infections - chemically induced Intracranial hemorrhage Ischemic Attack, Transient - drug therapy Japan Male Middle Aged Prospective Studies Registries Stroke - drug therapy Survival Analysis Treatment Outcome Warfarin Warfarin - adverse effects Warfarin - therapeutic use |
| title | Two-Year Outcomes of Anticoagulation for Acute Ischemic Stroke With Nonvalvular Atrial Fibrillation ― SAMURAI-NVAF Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T15%3A56%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Two-Year%20Outcomes%20of%20Anticoagulation%20for%20Acute%20Ischemic%20Stroke%20With%20Nonvalvular%20Atrial%20Fibrillation%E3%80%80%E2%80%95%20SAMURAI-NVAF%20Study&rft.jtitle=Circulation%20Journal&rft.au=Yoshimura,%20Sohei&rft.aucorp=SAMURAI%20Study%20Investigators&rft.date=2018-06-25&rft.volume=82&rft.issue=7&rft.spage=1935&rft.epage=1942&rft.pages=1935-1942&rft.issn=1346-9843&rft.eissn=1347-4820&rft_id=info:doi/10.1253/circj.CJ-18-0067&rft_dat=%3Cproquest_cross%3E2049932268%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2049932268&rft_id=info:pmid/29863095&rfr_iscdi=true |